1-(5-Bromo-3-methylpyridin-2-yl)piperazine → HCID 67381057, 화합물
반응식
[CH3:1][C@@H:2]1[CH2:6][O:5][C:4](=[O:7])[N:3]1[C:8]1[CH:16]=[CH:15][C:11]([C:12]([OH:14])=O)=[CH:10][CH:9]=1.[Br:17][C:18]1[CH:19]=[C:20]([CH3:30])[C:21]([N:24]2[CH2:29][CH2:28][NH:27][CH2:26][CH2:25]2)=[N:22][CH:23]=1>>[Br:17][C:18]1[CH:19]=[C:20]([CH3:30])[C:21]([N:24]2[CH2:25][CH2:26][N:27]([C:12]([C:11]3[CH:10]=[CH:9][C:8]([N:3]4[C@H:2]([CH3:1])[CH2:6][O:5][C:4]4=[O:7])=[CH:16][CH:15]=3)=[O:14])[CH2:28][CH2:29]2)=[N:22][CH:23]=1참가 물질
3
실험 절차
By reaction and treatment in the same manner as in Preparation Example 67 and using (R)-4-(4-methyl-2-oxooxazolidin-3-yl)benzoic acid (1.3 g) described in Preparation Example 37 and 1-(5-bromo-3-methylpyridin-2-yl)piperazine (1.5 g), (R)-3-{4-[4-(5-bromo-3-methylpyridin-2-yl)piperazine-1-carbonyl]phenyl}-4-methyloxazolidin-2-one (2.6 g) was obtained.
후처리
- customBy reaction and treatment in the same manner
- customas in Preparation Example 67